Compositions and methods for treating HIV/AIDS with immunotherapy
AssigneeLentigen Technology, Inc.
InventorsKim Anthony Gonda, Dina Schneider, Rimas Orentas, Boro Dropulic
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptors (CARs) containing HIV envelope antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing HIV-infection in a subject, and methods of making CAR T cells are also disclosed. Results of treating or preventing HIV-infection, and results of making CAR T cells are also disclosed.
Claims18
An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising at least one extracellular anti-HIV antigen binding domain, wherein the isolated nucleic acid encoding the extracellular anti-HIV envelope antigen binding domain comprises a nucleic sequence comprising SEQ ID NO:
- 69 or SEQ ID NO:
- 115, at least one transmembrane domain, and at least one intracellular signaling domain.
A pharmaceutical composition comprising an anti-HIV effective amount of a population of human T cells, wherein the population of human T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises at least one extracellular anti-HIV antigen binding domain comprising the amino acid sequence of SEQ ID NO:
- 70 or SEQ ID NO:
- 116, at least one linker domain, at least one transmembrane domain, at least one intracellular signaling domain, and wherein the population of T cells are T cells of a human subject having HIV/AIDS.
A method of treating HIV-related cancers or HIV/AIDS in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the population of T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR),
- wherein the CAR comprises at least one extracellular anti-HIV antigen binding domain, at least one linker or spacer domain, at least one transmembrane domain, and at least one intracellular signaling domain wherein the nucleic acid sequence encoding the extracellular anti-HIV antigen binding domain comprises a nucleic sequence comprising SEQ ID NO:
- 69, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, wherein the population of T cells are T cells of the subject having HIV/AIDS.
A method of treating HIV-related cancers or HIV/AIDS in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the population of T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR),
- wherein the CAR comprises at least one extracellular anti-HIV antigen binding domain, at least one linker or spacer domain, at least one transmembrane domain, and at least one intracellular signaling domain wherein the nucleic acid sequence encoding the extracellular anti-HIV antigen binding domain comprises a nucleic sequence comprising SEQ ID NO:
- 115, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, wherein the population of T cells are T cells of the subject having HIV/AIDS.
A method of treating HIV-related cancers or HIV/AIDS in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the population of T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR),
- wherein the CAR comprises at least one extracellular anti-HIV antigen binding domain, at least one linker or spacer domain, at least one transmembrane domain, and at least one intracellular signaling domain wherein the at least one extracellular anti-HIV antigen binding domain comprises the amino acid sequence of SEQ ID NO:
- 70, wherein the population of T cells are T cells of the subject having HIV/AIDS.
A method of treating HIV-related cancers or HIV/AIDS in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the population of T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR),
- wherein the CAR comprises at least one extracellular anti-HIV antigen binding domain, at least one linker or spacer domain, at least one transmembrane domain, and at least one intracellular signaling domain wherein the at least one extracellular anti-HIV antigen binding domain comprises the amino acid sequence of SEQ ID NO:
- 116, wherein the population of T cells are T cells of the subject having HIV/AIDS.
Dependencies are inferred from the claim text.